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Abstract
Aims/hypothesis An increased risk of fracture with canagliflozin vs placebo was reported from the CANagliflozin
cardioVascular Assessment Study (CANVAS) Program, with heterogeneity of findings identified between the two trials that
comprise the CANVAS Program, CANVAS and CANVAS-R. The objective of these analyses was to identify reasons for the
possibly different effects on fracture observed between CANVAS and CANVAS-R.
Methods This study was an analysis of two highly similar trials, CANVAS and CANVAS-R, conducted in 10,142 individuals
with type 2 diabetes and history or high risk of cardiovascular disease who received canagliflozin (pooled 100/300mg once daily)
or placebo. Outcomes assessed in this analysis were effects on adjudicated fractures overall and by type, location, association
with a fall, dose and follow-up time.
Results A total of 496 participants recorded ≥1 fracture event during follow-up (15.40 vs 11.93 per 1000 patient-years with
canagliflozin vs placebo; HR 1.26 [95%CI 1.04, 1.52]). There was significant heterogeneity in the effects on fracture (p = 0.005)
between CANVAS (n = 4330: HR 1.55 [95% CI 1.21, 1.97]) and CANVAS-R (n = 5812: HR 0.86 [95% CI 0.62, 1.19]). The
between-study heterogeneity in fracture risk was not clearly explained by differences in baseline characteristics, interactions of
randomised treatment with participant characteristics, dose effects, duration of follow-up, metabolic effects, adverse events
related to falls or adverse events possibly causing falls.
Conclusions/interpretation There was no evidence to explain clearly the fracture risk observed in the CANVAS Program or the
heterogeneity in fracture risk between the two studies. The recently reported null result for fracture in the Canagliflozin and Renal
Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial suggests that the observed association
in CANVAS is likely to be a chance finding, although an unidentified fall-related mechanism remains a possibility.
Trial registration: ClinicalTrials.gov NCT01032629, NCT01989754.
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CANVAS CANagliflozin cardioVascular Assessment
Study
CANVAS-R CANagliflozin cardioVascular Assessment
Study-Renal
CREDENCE Canagliflozin and Renal Events in Diabetes




DSMC Data and Safety Monitoring Committee
GLP-1 Glucagon-like peptide-1
IQR Interquartile range
PVD Peripheral vascular disease
RAAS Renin–angiotensin–aldosterone system
SBP Systolic BP
SGLT2 Sodium glucose co-transporter 2
Introduction
Individuals with type 2 diabetes mellitus have an elevated risk
of fracture [1], though bone mineral density is typically
preserved and may be increased in those with diabetes com-
pared with those without diabetes [2, 3]. Glucose-lowering
agents have varied effects on bone metabolism and fracture
risk—thiazolidinediones lead to bone loss and increase the
risk of fracture [4, 5], while sulfonylureas do not appear to
influence bone health. Incretin-based medications (glucagon-
like peptide-1 [GLP-1] receptor agonists and dipeptidyl
peptidase-4 [DPP-4] inhibitors) and metformin may have pro-
tective effects on bone quality [6, 7].
Canagliflozin, a sodium glucose co-transporter 2 (SGLT2)
inhibitor, acts to lower serum glucose by inhibiting renal tubu-
lar reabsorption of glucose. The CANagliflozin cardioVascular
Assessment Study (CANVAS) Program [8] integrated data
from two directly comparable, double-blind, randomised con-
trolled trials (CANVAS and CANVAS-Renal [CANVAS-R])
[9, 10] carried out amongst people with type 2 diabetes
mellitus at increased risk of cardiovascular disease. The trials
were designed to complete simultaneously when a prespecified
minimum number of cardiovascular events and a minimum
follow-up time were achieved [11]. The prespecified strategy
for analysis was to assess treatment effects in the combined
data across the two studies to maximise statistical power, with
assessment of the constancy of effects on the outcomes of
interest across the trials by including an interaction term.
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A routine interim review of the CANVAS trial performed
in 2013 by the Data and Safety Monitoring Committee
(DSMC) identified a higher incidence of fracture in the
canagliflozin group compared with the placebo group (HR
1.51 [95% CI 1.04, 2.19]) [12]. Effects of canagliflozin on
markers indicating some increase in bone turnover had been
reported previously, as had some reduction of bone mineral
density at the total hip, though not at other sites [13].
Following the DSMC report and further review, the US
Food and Drug Administration (FDA) issued a labelled warn-
ing about elevated fracture risk in patients treated with
canagliflozin. The other SGLT2 inhibitor that carries a warn-
ing related to fracture risk is dapagliflozin, which is restricted
to the USA and applies only to individuals with moderate
renal impairment [14].
CANVAS-R [10] was a second trial of canagliflozin per-
formed in parallel to CANVAS [9]. The overall CANVAS
Program findings comprising the integrated data from the
two trials and the results from the individual trials were report-
ed in 2017 [8]. Within the CANVAS Program, the effect of
canagliflozin compared with placebo on fracture risk was at-
tenuated (HR 1.26 [95% CI 1.04, 1.52]) compared with the
initial report from CANVAS (HR 1.51 [95% CI 1.04, 2.19])
[8, 12]. Furthermore, there was significant heterogeneity in the
effects of canagliflozin comparedwith placebo on fracture risk
observed between CANVAS (HR 1.55 [95% CI 1.21, 1.97])
and CANVAS-R (HR 0.86 [95% CI 0.62, 1.19]) (p homoge-
neity = 0.005), with no increase in fracture risk seen in
CANVAS-R, and no reason for the heterogeneity immediately
apparent [8].
The goal of these analyses was to explore the effects of
canagliflozin compared with placebo on fracture risk in
CANVAS compared with CANVAS-R and seek to understand
the heterogeneity between the two trials.
Methods
CANVAS Program design The study design, characteristics of
participants and the main results of the overall CANVAS
Program have previously been published [8–11]. In brief,
the CANVAS Program, comprising two similarly designed
and conducted trials, CANVAS and CANVAS-R, was de-
signed to assess the cardiovascular and renal safety and effi-
cacy of canagliflozin compared with placebo, and determine
how any potential benefits might balance against risks. There
were 667 centres in 30 countries in the two trials that were
scheduled for joint close-out and analysis when at least 688
cardiovascular events and a minimum of 78 weeks of follow-
up had been accrued for the last randomised participant, which
occurred in February 2017. The ethics committees at each site
approved the protocols for the two trials, and all participants
provided written informed consent. All procedures followed
were in accordance with the Helsinki Declaration of 1964, as
revised in 2013. The trials were registered at ClinicalTrials.
gov registration nos. NCT01032629, NCT01989754.
Participants Participant inclusion criteria were similar for
CANVAS and CANVAS-R. Differences potentially important
to fracture occurrence were that rosiglitazone use was an ex-
clusion criterion in CANVAS-R and there was some variation
in geographies from which participants were recruited.
Participants were those with type 2 diabetes mellitus (glycated
haemoglobin ≥53 mmol/mol [7.0%] and ≤ 91 mmol/mol
[10.5%]), aged 30 years or older with a history of symptomatic
atherosclerotic cardiovascular disease, or 50 years or olderwith
two or more risk factors for cardiovascular disease (duration of
diabetes ≥10 years, SBP >140 mmHg while on one or more
antihypertensive agents, current smoker, microalbuminuria or
macroalbuminuria, or HDL-cholesterol <1 mmol/l). A history
of fracture at entry to the trial was based upon reports made by
site investigators.
Randomisation, treatment and follow-up After a 2 week, sin-
gle-blind, placebo run-in period, participants were randomised
centrally through an interactive web response system using a
computer-generated randomisation schedule prepared by the
study sponsor using randomly permuted blocks. Participants
in CANVAS were assigned in a 1:1:1 ratio to canagliflozin
100 mg, canagliflozin 300 mg or matching placebo, and par-
ticipants in CANVAS-R were randomly assigned in a 1:1 ratio
to canagliflozin or matching placebo, administered at an initial
dose of 100mg once daily with optional up-titration to 300mg
from week 13. Participants and all study staff were masked to
individual treatment allocations until the completion of the
study. Use of other background therapy for glycaemic man-
agement, as well as prevention of cardiovascular outcomes
and other diseases was according to best practice instituted
in line with local guidelines.
After randomisation, participants had three visits in the first
year and were seen at 6 month intervals thereafter, with alter-
nating telephone follow-up between visits. Every follow-up
included enquiry about primary and secondary outcome
events and adverse events. Fracture events were recorded as
part of standard adverse event reporting from the commence-
ment of CANVAS, with more detailed data sought prospec-
tively from 21March 2014 after the initial report of a possible
fracture risk by the DSMC and updating of the case report
form. Data describing fracture type, location and other details
were sought to support a central review of all fractures by a
specialist adjudication committee throughout the entire dura-
tion of both CANVAS and CANVAS-R. Core information
was recorded by site investigators with copies of imaging
reports, diagnostic test data and medical records forwarded
in parallel. The updated electronic case report form was in
place from the start of CANVAS-R. Falls, regardless of their
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association with fracture events, were recorded as adverse
events identified from spontaneous self-reporting by the par-
ticipants or from questioning by the investigator at scheduled
follow-up. There was no specific diary or other approach im-
plemented to systematically record all falls. Participants who
prematurely discontinued study treatment continued sched-
uled follow-up wherever possible, with extensive efforts made
to obtain full outcome data for all serious adverse events,
including fracture, until the final follow-up window that
spanned from November 2016 to February 2017. Adverse
event reporting captured all adverse events (serious and non-
serious events) at the initiation of CANVAS but was limited to
just serious adverse events and adverse events of special in-
terest (which included fracture) from January 2014, after
canagliflozin was registered for marketing.
Outcomes The primary outcome of interest for this report was
all adjudicated fractures. Additional outcomes evaluated were
fractures of different types (low-trauma, high-trauma, patholog-
ical, stress and other), fractures at different locations (upper
limb, lower limb, spine, pelvis, skull or facial bone or thoracic
cage) and fractures that were, and were not, associated with a
fall. Intermediate markers related to bone metabolism, includ-
ing serum calcium, phosphorous, magnesium, alkaline phos-
phatase (ALP) and body weight, were also evaluated as were
effects of canagliflozin on falls (adverse events reported as falls
or as a result of falls) and adverse events that might lead to falls,
including volume depletion, hypoglycaemia and retinopathy.
Statistical analysis All analyses were based on the occurrence
of the first event of interest during follow-up. The effect of
canagliflozin on fracture risk was assessed in the modified
intention-to-treat set (participants who received at least one
dose of canagliflozin or placebo) using a Cox proportional
hazard model with treatment as the exploratory variable and
trial as the stratification factor. Annualised incidence rates per
1000 patient-years of follow-up were calculated for all out-
comes in addition to HRs and 95% CIs determined from the
model. We tested the homogeneity of treatment effects across
the two contributing trials by fitting the interaction term to the
model, and the same approach was used for testing compara-
bility of effects across subgroups defined by baseline partici-
pant characteristics. Baseline participant characteristics asso-
ciated with fracture risk were assessed using proportional haz-
ards models. Effects of canagliflozin on intermediate markers
related to bone metabolism and body weight were analysed
using an ANCOVA model with treatment as an independent
effect and adjusting for trial and baseline value. Difference in
the least squares means between those assigned to
canagliflozin compared with placebo were estimated from
the model. For adverse events possibly related to fracture,
the HR with 95% CI was estimated from the same form of
Cox regression model that was used to determine effects on
fracture. Effects on fracture were also estimated according to
whether the fracture event occurred on-treatment, within 7, 30
or 90 days of treatment discontinuation or longer after treat-
ment discontinuation. Cumulative event curves were plotted
and visually inspected to explore the evolution of fracture risk
over time. Analyses were initially done on the integrated
CANVAS Program dataset, and then done for CANVAS and
CANVAS-R separately. Effects of the 100 mg vs 300 mg
doses of canagliflozin were explored in the CANVAS
dataset alone. SAS Enterprise Guide version 7.1 (version no.
7.15 HF7 (7.100.5.6177) (64-bit); SAS Institute, Cary, NC,
USA) was used for statistical analyses.
Results
There were 10,142 participants in the overall CANVAS
Program (CANVAS, n = 4330 and CANVAS-R, n = 5812)
and 10,134 who received at least one dose of randomised
treatment (electronic supplementary material [ESM] Fig. 1).
In CANVAS-R, 73% of participants were up-titrated to the
300 mg dose. The mean follow-up time was 188.2 weeks
but varied between the two trials (CANVAS, 295.9 weeks
and CANVAS-R, 108.0 weeks). Overall mean age at baseline
was 63.3 years, 35.8% were women, mean duration of diabe-
tes was 13.5 years, 65.6% had a history of cardiovascular
disease and 21.8% reported a prior history of fracture. There
were multiple statistically significant differences between the
baseline characteristics of participants included in CANVAS
compared with CANVAS-R, but absolute differences between
the characteristics of participants in the two trials were mostly
small (Table 1).
Associations of baseline participant characteristics with frac-
ture risk There were 496 (4.9%) individuals who had a frac-
ture event during follow-up. Participants who had a fracture
event during follow-up were different from other trial partic-
ipants in terms of baseline demography, disease history, labo-
ratory tests, medications used for the management of diabetes
and cardiovascular risks. The absolute magnitudes of the dif-
ferences were small aside from the proportions of women
(49.4% vs 35.1%) and the proportions with a prior history of
fracture (33.9% vs 21.2%) (ESM Table 1). Univariable
modelling identified 20 baseline characteristics that were sig-
nificantly associated with fracture risk in the overall CANVAS
Program (Table 2). The pattern of associations of baseline
characteristics with fracture in the univariable analyses were
comparable across CANVAS and CANVAS-R except for his-
tory of hypertension, serum calcium, haematocrit, albumin-
uria and antithrombotic use where the associations of these
exposures with fracture risk varied between the trials (all p
heterogeneity <0.047) (Table 2 and ESM Table 2).
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Table 1 Baseline characteristics








Age, years 62.4 ± 8.0 64.0 ± 8.3 <0.001a,*
Female 1467 (33.9) 2164 (37.3) <0.001b,*
Race <0.001b,*
White 3177 (73.4) 4761 (82.0)
Asian 795 (18.4) 489 (8.4)
Black 105 (2.4) 230 (4.0)
Otherc 250 (5.8) 327 (5.6)
Region <0.001b,*
North America 1245 (28.8) 1181 (20.3)
Central and South America 167 (3.9) 854 (14.7)
Europe 1335 (30.9) 2271 (39.1)
ROW 1580 (36.5) 1501 (25.8)
Current smoker 775 (17.9) 1027 (17.7) 0.77b
Hypertension history 3792 (87.6) 5326 (91.7) <0.001b,*
Heart failure history 515 (11.9) 944 (16.3) <0.001b,*
Atrial fibrillation 229 (5.3) 384 (6.6) 0.006b,*
Duration of diabetes, years 13.4 ± 7.5 13.7 ± 7.9 0.09a
Microvascular disease
Retinopathy 864 (20.0) 1263 (21.7) 0.03b,*
Nephropathy 659 (15.2) 1113 (19.2) <0.001b,*
Neuropathy 1345 (31.1) 1764 (30.4) 0.45b
Atherosclerotic vascular disease historyd
Coronary 2374 (54.9) 3343 (57.6) 0.007b,*
Cerebrovascular 707 (16.3) 1249 (21.5) <0.001b,*
Peripheral 685 (15.8) 1426 (24.6) <0.001b,*
Any 2891 (66.8) 4427 (76.2) <0.001b,*
Cardiovascular disease historye 2548 (58.9) 4103 (70.7) <0.001b,*
Fracture history 989 (22.9) 1223 (21.1) 0.03b,*
Amputation history 77 (1.8) 160 (2.8) 0.001b,*
BMI, kg/m2 32.1 ± 6.2 31.9 ± 5.7 0.054a
Body weight, kg 91.1 ± 21.3 89.5 ± 19.4 <0.001a,*
BP, mmHg
SBP 136.3 ± 15.7 136.9 ± 15.8 0.046a,*
DBP 77.8 ± 9.7 77.6 ± 9.6 0.31a
HbA1c, mmol/mol 66 ± 9.8 67 ± 9.8 <0.001
a,*
HbA1c, % 8.2 ± 0.9 8.3 ± 0.9 <0.001
a,*
Cholesterol, mmol/l
Total 4.4 ± 1.2 4.4 ± 1.2 0.80a
HDL 1.2 ± 0.3 1.2 ± 0.3 0.001a,*
LDL 2.3 ± 0.9 2.3 ± 0.9 0.56a
Ratio of LDL to HDL 2.0 ± 0.9 2.1 ± 0.9 0.10a
Triacylglycerol, mmol/l 2.0 ± 1.4 2.1 ± 1.5 <0.001a,*
eGFR, ml min−1 [1.73 m]−2 77.2 ± 18.9 75.9 ± 21.6 0.001a,*
Calcium, mmol/l 2.4 ± 0.1 2.4 ± 0.1 0.01a,*
Phosphorous, mmol/l 1.2 ± 0.2 1.1 ± 0.2 <0.001a,*
Magnesium, mmol/l 0.8 ± 0.1 0.8 ± 0.1 <0.001a,*
ALP, U/l 76.3 ± 24.6 76.8 ± 25.4 0.34a
Haematocrit, % 41.8 ± 4.2 42.1 ± 4.1 <0.001a,*
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Effects of canagliflozin on all fractures, different types of frac-
ture and fractures at different sites In the overall CANVAS
Program, canagliflozin was associated with a higher risk of all
fracture compared with placebo, with a rate of 15.40 per 1000
patient-years amongst those assigned canagliflozin, and 11.93
per 1000 patient-years amongst those assigned placebo (Fig. 1).
The overall HR was 1.26 (95% CI 1.04, 1.52) but there was
significant heterogeneity in the effects on fracture (p = 0.005)
between the CANVAS trial (HR 1.55 [95% CI 1.21, 1.97]) and
the CANVAS-R trial (HR 0.86 [95% CI 0.62, 1.19]) [8]. The
cumulative event curves separated at about 12 months for the
overall CANVAS Program. For the individual trials, CANVAS
showed an immediate separation but for CANVAS-R there was
no separation at any time point (Fig. 1 and ESMTable 3). There
was no evidence within CANVAS that the risk of fracture as-
sociated with the 300mg dose of canagliflozin was greater than
the risk associated with the 100 mg dose (p = 0.34).
For the overall CANVAS Program, the point estimates of
effect were greater than unity for fractures at all locations and
for fractures of all types (except stress fracture and other frac-
ture), though for every one of these fracture subsets the 95%CI
crossed unity (Table 3). Different effects on low-trauma frac-
ture and lower limb fracture (both p interaction <0.05) drove
the difference in overall fracture between the individual trials
CANVAS and CANVAS-R, though point estimates of effect








Median albumin/creatinine ratio (IQR) 11.9 (6.6–36.3) 12.6 (6.7–46.7) 0.13f
Normoalbuminuria, no./total no. (%) 3090/4306 (71.8) 3916/5723 (68.4) <0.001g,*
Microalbuminuria, no./total no. (%) 966/4306 (22.4) 1297/5723 (22.7)
Macroalbuminuria, no./total no. (%) 250/4306 (5.8) 510/5723 (8.9)
Drug therapy
Insulin 2172 (50.2) 2921 (50.3) 0.92b
Sulfonylurea 2031 (46.9) 2328 (40.1) <0.001b,*
Metformin 3168 (73.2) 4652 (80.1) <0.001b,*
Thiazolidinediones 359 (8.3) 133 (2.3) <0.001b,*
α-Glucosidase inhibitors 117 (2.7) 135 (2.3) 0.23b
Glinides 62 (1.4) 0 (0.0) <0.001b,*
DPP-4 inhibitor 317 (7.3) 944 (16.3) <0.001b,*
GLP-1 receptor agonist 96 (2.2) 311 (5.4) <0.001b,*
Statin 3129 (72.3) 4467 (76.9) <0.001b,*
Antithrombotich 3102 (71.7) 4365 (75.2) <0.001b,*
RAAS inhibitor 3488 (80.6) 4625 (79.6) 0.23b
β-Blocker 2178 (50.3) 3242 (55.8) <0.001b,*
Diuretics 1900 (43.9) 2589 (44.6) 0.50b
Calcium channel blocker 1400 (32.4) 2043 (35.2) 0.003b,*
Analyses were performed on data from the on-treatment dataset
Data are mean ± SD or n (%), unless otherwise stated
a p value corresponds to the test for no difference between CANVAS and CANVAS-R from an ANCOVA model
b p value corresponds to Generalised Cochran–Mantel–Haenszel test for no general association
c Includes American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, multiple, other and
unknown
d Some participants had more than one type of atherosclerotic vascular disease
e A history of cardiovascular disease was defined as a history of symptomatic atherosclerotic vascular disease
(coronary, cerebrovascular or peripheral)
f p value corresponds to Wilcoxon rank sum test of equal medians
g p value corresponds to van Elteren test for no association
h Includes antiplatelets and anticoagulants
*p <0.05
IQR, interquartile range; ROW, rest of the world
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directionally different between the two trials. There was, once
again, no significant difference in fracture risk between the
100 mg and 300 mg doses of canagliflozin used in CANVAS
for any fracture type or for any fracture location (all p >0.26).
Effects of canagliflozin compared with placebo on fracture
risk were also comparable across participant subgroups defined
by a broad range of baseline characteristics. The only statistically
significant interaction (p = 0.03) was for recruitment sites in re-
gions with different levels of economic development (Fig. 2)
and there were no interactions by physical characteristics, base-
line disease history or use of concomitant medications.
Most participants who sustained a fracture experienced the
event while adherent to double-blind randomised treatment
(419/496) (ESM Table 4). The HR for fracture with
canagliflozin compared with placebo did not differ when anal-
yses included only participants who experienced fracture while
using randomised treatment or shortly after discontinuing
randomised treatment.
Effects of canagliflozin on falls and adverse events that might
lead to falls Canagliflozin use was associated with an in-
creased risk of adverse events or serious adverse events
Table 2 Baseline participant characteristics associated with fracture risk in univariate models in the CANVAS Program, CANVAS and CANVAS-R
Univariable HR (95% CI) p interactiona
CANVAS Program CANVAS CANVAS-R
Demographics
Age (1 year higher) 1.04 (1.03, 1.05)* 1.03 (1.02, 1.05)* 1.05 (1.03, 1.07)* 0.30
Female vs male 1.89 (1.58, 2.25)* 2.06 (1.67, 2.54)* 1.53 (1.11, 2.12)* 0.13
Race (white vs non-white) 1.95 (1.51, 2.52)* 2.10 (1.57, 2.81)* 1.53 (0.92, 2.53) 0.28
Race (Asian vs non-Asian) 0.50 (0.37, 0.69)* 0.44 (0.31, 0.63)* 0.89 (0.47, 1.69) 0.06
Region (Europe vs other) 1.34 (1.11, 1.60)* 1.27 (1.02, 1.58)* 1.50 (1.08, 2.08)* 0.40
Region (ROW vs others) 0.64 (0.52, 0.78)* 0.66 (0.52, 0.83)* 0.57 (0.37, 0.88)* 0.56
Disease history
Hypertension history (Yes vs No) 0.89 (0.68, 1.16) 1.03 (0.75, 1.43) 0.57 (0.35, 0.93)* 0.047*
Atrial fibrillation history (Yes vs No) 1.27 (0.89, 1.81) 1.53 (1.02, 2.30)* 0.82 (0.40, 1.67) 0.14
Duration of diabetes (year greater) 1.04 (1.03, 1.05)* 1.04 (1.02, 1.05)* 1.04 (1.02, 1.05)* 0.94
Retinopathy history (Yes vs No) 1.31 (1.07, 1.60)* 1.15 (0.89, 1.48) 1.72 (1.21, 2.43)* 0.06
Neuropathy history (Yes vs No) 1.21 (1.00, 1.45)* 1.32 (1.07, 1.64)* 0.95 (0.66, 1.36) 0.12
Coronary disease history (Yes vs No) 0.85 (0.71, 1.01) 0.79 (0.64, 0.98)* 0.99 (0.71, 1.37) 0.28
Fracture history (Yes vs No) 1.83 (1.52, 2.20)* 1.63 (1.31, 2.05)* 2.37 (1.69, 3.30)* 0.07
Clinical and laboratory parameters
DBP (1 mmHg greater) 0.98 (0.97, 0.99)* 0.98 (0.97, 0.99)* 0.98 (0.96, 0.99)* 0.61
HDL-cholesterol (1 mmol/l greater) 1.65 (1.28, 2.13)* 1.76 (1.32, 2.35)* 1.37 (0.83, 2.26) 0.39
LDL-cholesterol (1 mmol/l greater) 0.91 (0.82, 1.00) 0.97 (0.86, 1.08) 0.78 (0.65, 0.95)* 0.06
eGFR (1 ml min−1 [1.73 m]−2 greater) 0.99 (0.99, 1.00)* 1.00 (0.99, 1.00) 0.99 (0.98, 1.00)* 0.13
Serum calcium (1 mmol/l greater) 0.72 (0.35, 1.49) 1.25 (0.53, 2.92) 0.09 (0.02, 0.45)* 0.005*
ALP (1 U/l greater) 1.00 (1.00, 1.01)* 1.00 (1.00, 1.01)* 1.00 (0.99, 1.01) 0.27
Haematocrit (1% greater) 0.97 (0.95, 0.99)* 0.99 (0.97, 1.02) 0.92 (0.88, 0.96)* 0.002*
Albuminuria (macro or micro vs normal) 1.12 (0.92, 1.35) 0.96 (0.76, 1.22) 1.53 (1.10, 2.13)* 0.03*
Drug therapy
Insulin (Yes vs No) 1.42 (1.19, 1.70)* 1.39 (1.12, 1.71)* 1.52 (1.09, 2.12)* 0.64
Sulfonylurea (Yes vs No) 0.74 (0.62, 0.89)* 0.77 (0.62, 0.95)* 0.66 (0.47, 0.94)* 0.47
Metformin (Yes vs No) 0.72 (0.59, 0.87)* 0.71 (0.57, 0.89)* 0.74 (0.51, 1.08) 0.83
Statin (Yes vs No) 1.25 (1.01, 1.54)* 1.17 (0.91, 1.49) 1.52 (0.98, 2.36) 0.30
Antithrombotic (Yes vs No) 0.98 (0.81, 1.20) 0.85 (0.68, 1.06) 1.54 (1.00, 2.35)* 0.02*
Diuretics (Yes vs No) 1.35 (1.13, 1.61)* 1.39 (1.13, 1.72)* 1.24 (0.90, 1.72) 0.56
Canagliflozin treatment (Yes vs No) 1.26 (1.04, 1.52)* 1.55 (1.21, 1.97)* 0.86 (0.62, 1.19) 0.005*
a p interaction between CANVAS and CANVAS-R
*p <0.05
ROW, rest of the world
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attributed to falls in CANVAS, with a similar effect observed
for adverse events related to volume depletion. No corre-
sponding increases in falls reported as serious adverse events
was observed in CANVAS-R and in neither trial was there a
clear effect on hypoglycaemia or retinopathy. There was evi-
dence in CANVAS that falls occurred at greater rates with the
300 mg compared with 100 mg dose of canagliflozin (p =
0.01) (Table 4). Across the overall CANVAS Program, there
were 200 fractures identified as associated with a fall, 52 that
were identified as not associated with a fall and 267 for which
the relationship with a fall was uncertain. An adverse effect of
canagliflozin on fracture risk in CANVAS was apparent for
fractures with an unclear association with fall.
Effects of canagliflozin on biomarkers of bone metabolism
Effects of canagliflozin on serum calcium, serum phosphorous
and serum magnesium differed between CANVAS and
CANVAS-R (all p interaction <0.001) though mean levels
remained within normal ranges throughout the studies
(Table 4). Serum calcium was increased in CANVAS but not
CANVAS-R; phosphorous was decreased in CANVAS-R but
not CANVAS; and magnesium was increased in both studies,
but to a greater extent in CANVAS and especially in the
300 mg dose group. ALP was unchanged in all analyses and
bodyweight was decreased consistently with no heterogeneity
by trial and no difference by dose in CANVAS (p = 0.06).
Effects of canagliflozin compared with placebo on calcium,
phosphorous and magnesium did not differ between
CANVAS and CANVAS-R in analyses restricted to assays
done while participants were using randomised treatment
(ESM Table 5). Likewise, differences between studies were
attenuated in analyses that compared biomarker levels be-
tween canagliflozin and placebo at the same follow-up time
in both trials (130 weeks).
Discussion
We could find no definitive explanation for either the fracture
risk observed in the overall CANVAS Program or for the dif-
ference in fracture risk between CANVAS and CANVAS-R. In
practice, however, most fractures are the result of a fall [15]
and, in the absence of a clear signal for metabolic bone disease,
this remains the most plausible mechanism by which a real
effect on fracture in CANVAS would be mediated. While the
analyses themselves identified no direct evidence for an asso-
ciation between falls and fracture risk, the available data to
assess such an association were limited and a fall-related mech-
anism of action may have been missed. The chief alternative
possibility is that the observed increase in fracture risk in the
CANVAS Program is a chance finding. The likelihood of
chance being the explanation is amplified by the absence of




Fig. 1 Time to first fracture in (a) CANVAS Program, (b) CANVAS vs
CANVAS-R and (c) canagliflozin 100 mg vs 300 mg vs placebo in
CANVAS
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of the fracture risk during serial six monthly data and safety
reviews and the inconsistency of the findings for fracture across
the two constituent trials. The absence of a fracture risk in the
recently reported CREDENCE (Canagliflozin and Renal
Events in Diabetes with Established Nephropathy Clinical
Evaluation) trial [16] of canagliflozin amongst participants with
type 2 diabetes and chronic kidney disease increases the likeli-
hood of chance being the correct interpretation of the outlying
CANVAS result. Alternatively, if the fracture risk is real, then
use of the 100 mg dosing strategy employed in CANVAS-R
and CREDENCE might have ameliorated the risk of fracture,
though further investigation would be required to confirm this.
The other large completed trials of an SGLT2 inhibitor, the
EMPA-REG OUTCOME trial and the DECLARE
(Dapagliflozin Effect on Cardiovascular Events)–TIMI 58
trial, identified no risk of fracture [17–19], and the labelled
fracture risk for dapagliflozin [14] relates only to individuals
with moderate renal impairment and is based on a very small
number of events. A meta-analysis of all available fracture
data for SGLT2 inhibitors did not identify an overall risk of
fracture, but there was some evidence of heterogeneity be-
tween compounds that was driven substantively by the data
from CANVAS [20]. Observational studies of SGLT2 inhibi-
tor use and fracture risk have identified no clear increase in
risk [21, 22].
Our detailed analyses of the CANVAS Program identified
multiple and mostly expected observational associations of
baseline patient characteristics with the risk of subsequent
fracture. Placebo group rates of fracture in CANVAS-R were
marginally higher than in CANVAS, but these rate differences
provide no explanation for the different effects of the drug
across the two studies. Where unanticipated associations were
observed, or where there were differences in the associations of
risk factors with fracture between CANVAS and CANVAS-R,
the differences were small and there was no discernible pattern
or identifiable mechanistic pathway that was obviously linked
to the causation of fracture. The multiple analyses performed
increased the likelihood of chance significant findings, and this
may be the explanation for some or all of these observations.
Extensive investigation of baseline characteristics as possible
modifiers of the effect of canagliflozin on fracture risk using
subgroup analyses, likewise, could identify no reason for either
the association of canagliflozin with fracture risk in the overall
CANVAS Program or explain the differences in effects
between CANVAS and CANVAS-R. While statistical power
to detect interactions with randomised treatment was onlymod-
erate, and these analyses could be affected by the heterogeneity
between the two trials, strong effects able to explain the large
difference in fracture risk between trials are unlikely to have
been missed.
An increased risk of falling caused by complications of
diabetes such as retinopathy or neuropathy, or side effects
of glucose-lowering agents such as hypoglycaemia or
hypovolaemia, is a plausible mechanism for the reported
increased risk of fracture amongst individuals with type 2
diabetes [23, 24]. It has also been proposed as an explana-
tion for reported greater fracture risks in sites that are less
economically developed. These analyses did not identify
direct evidence of an increased risk of fall-related fracture,
but the data are limited because adverse event reporting
typically focuses on the outcome of events rather than the
mechanism leading to the event. There was no systematic
recording of all falls during the trials, and the systematic
collection of information about falls occurring at the time
of fracture was only implemented after the initial signal for
fracture risk was identified in 2013. Of all the fracture
events analysed, information about the presence or absence
of a concurrent fall was available for less than half because
retrospective data collection was not able to reliably eluci-
date this information for historical events.
Although data on falls in general or falls reported as ad-
verse events was not systematically collected throughout the
duration of the CANVAS Program, the data suggest that
canagliflozin treatment may increase the risk of falls.
Canagliflozin was also associated with an increased risk of
volume depletion events, findings which provide some indi-
rect support for a fall-related mechanism driving the increase
in fracture risk. The differences in the effects of canagliflozin
on the risk of falls and volume depletion events in CANVAS
compared with CANVAS-R align with the different effects on
fracture between the two trials. However, these data require
cautious interpretation—while the null effect on falls and vol-
ume depletion events in CANVAS-R could be real, perhaps
due to a more cautious up-titration of dose in CANVAS-R
amongst investigators sensitised to the risk of fracture, it is
also possible that the collection of only serious adverse events
in CANVAS-R reduced the capacity to detect effects on falls
and volume depletion events, which were frequently
categorised as non-serious. In addition, the possibility that
physicians may have been able to ameliorate fracture risk by
avoiding the higher dose or concomitant BP-lowering thera-
pies amongst those with the potential for harm presupposes
that the 300 mg dose of canagliflozin is associated with a
greater risk than the 100 mg dose. A dose response effect
was observed for the effect on falls but not for other adverse
events possibly related to fall risk, or fracture risk itself.
Moreover, the 100 mg dose of canagliflozin was associated
Fig. 2 Effects of canagliflozin on fracture in participant subgroups in the
CANVAS Program. aAccording to the 2018 World Bank open data
(https://data.worldbank.org/): sites with high economic levels include
Australia, Belgium, Canada, Czech Republic, Germany, Spain, Estonia,
France, UK, Hungary, Israel, Italy, South Korea, Taiwan, Luxembourg,
Netherlands, Norway, New Zealand, Poland, Sweden and USA; sites
with low or middle economic levels include Argentina, Brazil, China,
Colombia, India, Mexico, Malaysia, Russia and Ukraine. PVD,
peripheral vascular disease; ROW, rest of the world
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with an increased risk of fracture, but there were no detectable
effects of the 100 mg dose on either fall events or volume
depletion events. The likelihood that the different dosing reg-
imens explains the different effects of canagliflozin on fracture
between CANVAS and CANVAS-R is further reduced by the
observation that the event curves for the canagliflozin 100 mg
and 300 mg doses were overlapping until about 2.5 years into
follow-up. The different follow-up durations in CANVAS
compared with CANVAS-R also fail to provide an explana-
tion for the differences in the effects observed between the two
trials, with adverse effects clearly apparent early in CANVAS
but not in CANVAS-R.
Detailedmarkers of bonemetabolismwere not measured in
the CANVAS Program but there were effects of canagliflozin
compared with placebo on mean levels of serum calcium,
phosphorous and magnesium, and these differed between
CANVAS and CANVAS-R. The absolute magnitude of all
effects on these indicators was small and inconsistent, and
unlikely to be of clinical significance. There is no identified
mechanism by which the observed changes would explain the
overall effect on fracture or the observed heterogeneity in the
risk of fracture between CANVAS and CANVAS-R. In part,
the differences in the effects on these biomarkers between the
two trials may be a result of the different durations of follow-
up, since heterogeneity was much reduced when analyses
were done at comparable follow-up times when mean adher-
ence to treatment was more comparable. However, the fact
that the increased risk of fracture was observed in CANVAS
almost immediately and not observed in CANVAS-R over
2.5 years suggests that any time-dependent effects on calcium,
phosphorous or magnesium, if real, do not explain the hetero-
geneity in fracture risk between CANVAS and CANVAS-R.
In the absence of external data describing substantive adverse
effects of canagliflozin [25, 26], or other SGLT2 inhibitors, on
markers of bone turnover, a pathological mechanism based on
bone metabolism effects seems an unlikely cause of the frac-
tures observed in CANVAS. Sex is an important determinant
of fracture risk, and while not identified as a factor likely to
explain the different risks observed in CANVAS vs
CANVAS-R, the under-representation of women in the trials
reduced the power to assess the effects of sex and represents
an ongoing challenge to trialists.
In conclusion, we could find no clear explanation for either
the fracture risk observed in the CANVAS Program or the
difference in fracture risk observed in CANVAS compared
with CANVAS-R. In practice, however, most fractures are
caused by falls and the observed association is likely a conse-
quence of either an unidentified fall-related mechanism or else
a chance finding. The null finding for fracture risk with
canagliflozin in the recently completed CREDENCE trial
has provided important additional insight and somewhat in-
creases the likelihood that the adverse effect observed in
CANVAS was a spurious finding.
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